Amplia Therapeutics Ltd (ASX:ATX) has had an abstract describing its ACCENT clinical trial of AMP945 in first-line patients with advanced pancreatic cancer accepted for presentation at a major pancreatic cancer conference in the US.
The presentation will take place at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer from September 13-16 in Boston, MA.
It will be titled ‘Rationale for the use of pulsed rather than continual dosing of the novel Focal Adhesion Kinase inhibitor AMP945 in pancreatic cancer’ and will describe the scientific rationale and clinical trial design for ACCENT.
Attracts leading cancer researchers
This trial is open for recruitment and has been registered on ClinialTrials.gov with an identifier number of NCT05355298.
In a statement, Amplia, which is developing new approaches for the treatment of cancer and fibrosis, said: “The AACR special topic meetings attract the world’s leading cancer researchers who are working at the cutting edge of cancer research and new drug development.
"We’re delighted to have Amplia’s work accepted for presentation in this forum and expect it will raise awareness in the global clinical community of AMP945 and its potential in this devastating cancer.”
Amplia Therapeutics is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.
FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).